First Time Loading...

Legend Biotech Corp
NASDAQ:LEGN

Watchlist Manager
Legend Biotech Corp Logo
Legend Biotech Corp
NASDAQ:LEGN
Watchlist
Price: 56.93 USD 1.84% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. [ Read More ]

The intrinsic value of one LEGN stock under the Base Case scenario is 52.93 USD. Compared to the current market price of 56.93 USD, Legend Biotech Corp is Overvalued by 7%.

Key Points:
LEGN Intrinsic Value
Base Case
52.93 USD
Overvaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Legend Biotech Corp

Backtest LEGN Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LEGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Legend Biotech Showcases Strong CARVYKTI Sales
2023-Q4 Earnings Call

Legend Biotech Showcases Strong CARVYKTI Sales

Legend Biotech celebrates a landmark year as their leading CAR-T therapy, CARVYKTI, secures positive opinions for expansion in Europe and is set for an extended launch in the US. The therapy achieved a rapid market foothold with $0.5 billion in sales. For Q4 2023 alone, sales surged to $159 million, propelled by manufacturing efficiency and market share gains. The company's solid financial position, with a cash reserve of $1.3 billion, underscores the potential for sustained growth and investment in production, committing to a supply target of 10,000 patients by 2025. Revenue is up 189% year-over-year, but net losses increased slightly, from $446.3 million in 2022 to $518.3 million in 2023. Legend remains on track with its finances and is strategically poised for expansion and scale, planning further capacity increases for CARVYKTI and initiating trials in other cancers, all while projecting a financial runway through 2025.

Financials

Balance Sheet Decomposition
Legend Biotech Corp

Current Assets 1.5B
Cash & Short-Term Investments 1.3B
Receivables 100m
Other Current Assets 88.7m
Non-Current Assets 350.8m
PP&E 189.2m
Intangibles 4.1m
Other Non-Current Assets 157.5m
Current Liabilities 216.4m
Accounts Payable 153m
Other Current Liabilities 63.5m
Non-Current Liabilities 380.8m
Long-Term Debt 325.5m
Other Non-Current Liabilities 55.3m
Efficiency

Earnings Waterfall
Legend Biotech Corp

Revenue
285.1m USD
Cost of Revenue
-144.2m USD
Gross Profit
140.9m USD
Operating Expenses
-583.1m USD
Operating Income
-442.2m USD
Other Expenses
-76m USD
Net Income
-518.3m USD

Free Cash Flow Analysis
Legend Biotech Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

LEGN Profitability Score
Profitability Due Diligence

Legend Biotech Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive Gross Profit
30/100
Profitability
Score

Legend Biotech Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

LEGN Solvency Score
Solvency Due Diligence

Legend Biotech Corp's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Low D/E
72/100
Solvency
Score

Legend Biotech Corp's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LEGN Price Targets Summary
Legend Biotech Corp

Wall Street analysts forecast LEGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LEGN is 88.01 USD with a low forecast of 65.65 USD and a high forecast of 105 USD.

Lowest
Price Target
65.65 USD
15% Upside
Average
Price Target
88.01 USD
55% Upside
Highest
Price Target
105 USD
84% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

LEGN Price
Legend Biotech Corp

1M 1M
-16%
6M 6M
-15%
1Y 1Y
+22%
3Y 3Y
+102%
5Y 5Y
+54%
10Y 10Y
+54%
Annual Price Range
56.93
52w Low
46.28
52w High
76.5
Price Metrics
Average Annual Return 16.29%
Standard Deviation of Annual Returns 50.01%
Max Drawdown -45%
Shares Statistics
Market Capitalization 10.4B USD
Shares Outstanding 182 288 400
Percentage of Shares Shorted 10.8%

LEGN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Legend Biotech Corp Logo
Legend Biotech Corp

Country

United States of America

Industry

Biotechnology

Market Cap

10.4B USD

Dividend Yield

0%

Description

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 1,071 full-time employees. The company went IPO on 2020-06-04. is a clinical-stage biopharmaceutical company. The firm is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR- B38M (cilta-cel), is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies, including multiple myeloma (MM). The firm have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). The firm is also developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL. The company also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.

Contact

NEW JERSEY
Somerset
2101 Cottontail Lane
+17323175050.0
https://legendbiotech.com/

IPO

2020-06-04

Employees

1 071

Officers

CEO & Director
Dr. Ying Huang Ph.D.
Chief Financial Officer
Ms. Lori A. Macomber CPA
Vice President of Global Operations
Mr. Doug Wallace
Chief Scientific Officer & Head of Business Development
Dr. Guowei Fang Ph.D.
Senior Manager of Investor Relations
Joanne Choi
General Counsel
Mr. James Pepin J.D.
Show More
Executive Director of Strategic Marketing & Corporate Communications
Deborah Wong
VP & Global Head of Human Resources
Ms. Elaine Qian
Senior Vice President of Technical Operations
Ms. Liz Gosen
Senior Vice President of Global Regulatory Affairs
Dr. Yuhong Qiu Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one LEGN stock?

The intrinsic value of one LEGN stock under the Base Case scenario is 52.93 USD.

Is LEGN stock undervalued or overvalued?

Compared to the current market price of 56.93 USD, Legend Biotech Corp is Overvalued by 7%.